Micrus Endovascular Launches Cerecyte 18 Microcoil for Treatment of Large Cerebral Aneurysms.

SUNNYVALE, Calif. -- Micrus Endovascular Corporation (Nasdaq:MEND) today announced the market launch of its .018-inch-diameter microcoil, Cerecyte(R) 18, which expands the Company's Cerecyte product line to include additional microcoils that enable the treatment of large cerebral aneurysms. Cerecyte 18 incorporates the same bioactive technology utilized in the Company's other Cerecyte microcoils, which independent researchers suggest may improve outcomes, as presented in October 2005 at the 8th Congress of the World Federation of Interventional and Therapeutic Neuroradiology.

"With the availability of Cerecyte 18 and the Presidio(TM) microcoil, also launched this month, we now provide physicians with an expanded range of coil options to treat large cerebral aneurysms, which represent approximately 20% of all cerebral embolic coiling procedures. Both Presidio and Cerecyte 18 demonstrate the same handling and ease-of-use characteristics exhibited in our bare platinum microcoils," said John Kilcoyne, Micrus Endovascular president and CEO.

"This launch marks another milestone in our strategy to bring new value-added products to market," he added.

About Micrus Endovascular Corporation

Micrus Endovascular develops, manufactures and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists and neurosurgeons primarily to treat cerebral aneurysms responsible for hemorrhagic stroke, a significant cause of death in the United States. The Micrus product line enables physicians to gain access to the brain in a minimally invasive manner through the vessels of the circulatory system. Micrus' proprietary, three-dimensional microcoils are unique in that they automatically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells accessory devices and products used in conjunction with its microcoils.

Forward-Looking Statements

Micrus, from time to time, may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the Company's dependence upon the increased adoption of embolic coiling as a procedure to treat cerebral aneurysms, the Company's limited operating history and history of significant operating losses, the Company's involvement in patent litigation with Boston Scientific Corporation, fluctuations in quarterly operating results, which are difficult to predict, the Company's dependence on developing new products or product enhancements, challenges associated with rapid growth, challenges associated with complying with applicable state, federal and international regulations related to sales of medical devices and governing our relationships with physicians and other consultants, the Company's ability to compete with large, well-established medical device manufacturers with significant resources, the Company's dependence on obtaining timely U.S. Food and Drug Administration (FDA) as well as applicable international regulatory clearances and approvals for our future products or product enhancements, and other risks as detailed from time to time in the Company's final prospectus dated June 16, 2005, and reports and filings with the Securities and Exchange Commission under the Securities Exchange Act of 1934. All forward-looking statements in this release represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update forward-looking statements.